Literature DB >> 3595704

Verapamil-induced changes in digoxin kinetics in cirrhosis.

I Maragno, C Gianotti, P F Tropeano, V Rodighiero, R M Gaion, C Paleari, R Prandoni, L Menozzi.   

Abstract

The influence of a single low dose of verapamil (80 mg) on the serum levels of digoxin (single dose of 0.5 mg) was studied in 6 patients with hepatic cirrhosis and in 6 healthy volunteer controls. In the cirrhotic patients verapamil increased the peak serum level and the total AUC of digoxin by 98% and 32%, respectively. There was an associated 23% decrease in the renal digoxin clearance. In normal subjects only marginal alterations in digoxin kinetics were observed following verapamil administration. The results indicate that cirrhosis magnifies the influence of verapamil on digoxin kinetics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595704     DOI: 10.1007/bf00607580

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Interaction between digoxin and calcium antagonists and antiarrhythmic drugs.

Authors:  G G Belz; W Doering; R Munkes; J Matthews
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

2.  Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.

Authors:  J B Schwartz; D Keefe; R E Kates; E Kirsten; D C Harrison
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

3.  The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; K K Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

5.  Digoxin-verapamil interaction.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; F Nielsen-Kudsk
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

6.  Effect of coadministration of verapamil and quinidine on serum digoxin concentration.

Authors:  W Doering
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Influence of verapamil on the inotropism and pharmacokinetics of digoxin.

Authors:  K E Pedersen; P Thayssen; N A Klitgaard; B D Christiansen; F Nielsen-Kudsk
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Verapamil-induced changes in digoxin kinetics and intraerythrocytic sodium concentration.

Authors:  K E Pedersen; B D Christiansen; K Kjaer; N A Klitgaard; F Nielsen-Kudsk
Journal:  Clin Pharmacol Ther       Date:  1983-07       Impact factor: 6.875

9.  The influence of verapamil on serum digoxin concentration.

Authors:  H O Klein; R Lang; E Weiss; E Di Segni; C Libhaber; J Guerrero; E Kaplinsky
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

  9 in total
  3 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 2.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 3.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.